FDA Warning Letters and 510(k) Predicate Research

When FDA clears a 510(k), it determines that the device is substantially equivalent to a predicate. That determination is based on the submission — the intended use, technological characteristics, and any performance data provided. What happens after clearance is a separate matter.

FDA's Center for Devices and Radiological Health issues warning letters when inspections find that a manufacturer's quality system, manufacturing practices, or post-market obligations fall short of regulatory requirements. These letters are public record. They tell you something the clearance database doesn't: how a manufacturer has responded to ongoing FDA oversight.

What a warning letter actually means

A CDRH warning letter is FDA's principal means of achieving prompt voluntary compliance. It's issued when an inspection finds significant violations — typically of the Quality System Regulation (now QMSR under ISO 13485), current Good Manufacturing Practices, or post-market reporting requirements.

Common citations in device warning letters include:

• Inadequate CAPA (corrective and preventive action) procedures
• Failure to file MDRs (medical device reports) for adverse events
• Design control deficiencies
• Inadequate complaint handling
• Premarket approval violations — marketing a device without the required clearance

An open warning letter means FDA has identified violations and the manufacturer hasn't yet demonstrated adequate correction. A closed letter means FDA has reviewed the firm's corrective actions and found them sufficient.

Why this matters for predicate selection

A warning letter doesn't invalidate a predicate. A cleared device remains legally marketed regardless of the manufacturer's subsequent compliance history. But warning letter history is relevant to predicate research in several practical ways.

First, if a manufacturer has received a CDRH warning letter citing CGMP or quality system violations for the same device type you're using as a predicate, FDA may scrutinize the manufacturing standards behind the original clearance more carefully. This is especially true if the warning letter reveals that the manufacturer's quality system was deficient during or shortly after the period when the predicate was cleared.

Second, if the warning letter cites premarket approval violations — the manufacturer marketed a device modification without a new 510(k) — it raises questions about whether the cleared predicate represents the device as it was actually manufactured and sold.

Third, for enterprise buyers and partners who research the regulatory history of devices their products interact with, a predicate manufacturer with an open warning letter introduces risk that's worth documenting in your submission strategy.

How to check warning letter history

FDA publishes all warning letters on its website, searchable by company name, issuing office, subject, and date. CDRH letters are filterable separately from drug and food letters. The search interface supports keyword search against the full letter text.

In practice, checking warning letter history for each predicate candidate adds time to a research workflow that's already fragmented across multiple FDA databases. The information is public — the friction is in aggregating it alongside the clearance record you're already reviewing.

Incorporating warning letter history into predicate decisions

Warning letter history is one input among many in predicate selection — not a disqualifying factor on its own, but relevant context. A predicate from a manufacturer with an open CDRH warning letter isn't automatically a weaker choice. A predicate from a manufacturer with repeated citations for CAPA failures and adverse event reporting violations warrants more careful consideration.

The goal is to understand the full regulatory picture around a predicate before you file — not to find a reason to reject candidates, but to ensure your submission reflects accurate information about the device type's history.